356 related articles for article (PubMed ID: 30121825)
1. Objective impacts of tadalafil on storage and voiding function in male patients with benign prostatic hyperplasia: 1-year outcomes from a prospective urodynamic study.
Matsukawa Y; Takai S; Majima T; Funahashi Y; Sassa N; Kato M; Yamamoto T; Gotoh M
World J Urol; 2019 May; 37(5):867-872. PubMed ID: 30121825
[TBL] [Abstract][Full Text] [Related]
2. Effects of tadalafil on storage and voiding function in patients with male lower urinary tract symptoms suggestive of benign prostatic hyperplasia: A urodynamic-based study.
Matsukawa Y; Majima T; Matsuo K; Funahashi Y; Kato M; Yamamoto T; Gotoh M
Int J Urol; 2018 Mar; 25(3):246-250. PubMed ID: 29164680
[TBL] [Abstract][Full Text] [Related]
3. Effects of dutasteride on storage and voiding symptoms in male patients with lower urinary tract symptoms as a result of benign prostatic obstruction: the 1-year outcomes from a prospective urodynamic study.
Matsukawa Y; Gotoh M; Kato M; Funahashi Y; Narita M; Mitsui K
Int J Urol; 2014 Aug; 21(8):826-30. PubMed ID: 24661225
[TBL] [Abstract][Full Text] [Related]
4. Tadalafil Improves Symptoms, Erectile Function and Quality of Life in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (KYU-PRO Study).
Takahashi R; Miyazato M; Nishii H; Sumino Y; Takayama K; Onzuka M; Oshiro T; Saito S; Fujimoto N; Mimata H; Eto M
Low Urin Tract Symptoms; 2018 Jan; 10(1):76-83. PubMed ID: 29341501
[TBL] [Abstract][Full Text] [Related]
5. Administration of daily 5 mg tadalafil improves endothelial function in patients with benign prostatic hyperplasia.
Amano T; Earle C; Imao T; Matsumoto Y; Kishikage T
Aging Male; 2018 Mar; 21(1):77-82. PubMed ID: 28830281
[TBL] [Abstract][Full Text] [Related]
6. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
[TBL] [Abstract][Full Text] [Related]
7. Videourodynamic findings of lower urinary tract dysfunctions in men with persistent storage lower urinary tract symptoms after medical treatment.
Jiang YH; Wang CC; Kuo HC
PLoS One; 2018; 13(2):e0190704. PubMed ID: 29462145
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of tadalafil vs tamsulosin in lower urinary tract symptoms (LUTS) as a result of benign prostate hyperplasia (BPH)-open label randomised controlled study.
Singh I; Tk A; Gupta S
Int J Clin Pract; 2020 Aug; 74(8):e13530. PubMed ID: 32542854
[TBL] [Abstract][Full Text] [Related]
9. Tadalafil - a therapeutic option in the management of BPH-LUTS.
Carson CC; Rosenberg M; Kissel J; Wong DG
Int J Clin Pract; 2014 Jan; 68(1):94-103. PubMed ID: 24341303
[TBL] [Abstract][Full Text] [Related]
10. Current medical treatment of lower urinary tract symptoms/BPH: do we have a standard?
Silva J; Silva CM; Cruz F
Curr Opin Urol; 2014 Jan; 24(1):21-8. PubMed ID: 24231531
[TBL] [Abstract][Full Text] [Related]
11. Urodynamic effects of dutasteride add-on therapy to alpha-adrenergic antagonist for patients with benign prostatic enlargement: prospective pressure-flow study.
Wada N; Kita M; Hashizume K; Matsumoto S; Kakizaki H
Neurourol Urodyn; 2013 Nov; 32(8):1123-7. PubMed ID: 23861329
[TBL] [Abstract][Full Text] [Related]
12. A randomized controlled study of the efficacy of tadalafil monotherapy versus combination of tadalafil and mirabegron for the treatment of persistent overactive bladder symptoms in men presenting with lower urinary tract symptoms (CONTACT Study).
Yamanishi T; Kaga K; Sakata K; Yokoyama T; Kageyama S; Fuse M; Tokunaga S
Neurourol Urodyn; 2020 Feb; 39(2):804-812. PubMed ID: 31961963
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of Tadalafil Therapy and Changes in Oxidative Stress Levels in Male Patients with Lower Urinary Tract Symptoms and Overactive Bladder.
Matsuo T; Miyata Y; Araki K; Mukae Y; Otsubo A; Ohba K; Sakai H
Low Urin Tract Symptoms; 2020 Jan; 12(1):47-53. PubMed ID: 31407871
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.
Porst H; Kim ED; Casabé AR; Mirone V; Secrest RJ; Xu L; Sundin DP; Viktrup L;
Eur Urol; 2011 Nov; 60(5):1105-13. PubMed ID: 21871706
[TBL] [Abstract][Full Text] [Related]
15. Prostatic stromal inflammation is associated with bladder outlet obstruction in patients with benign prostatic hyperplasia.
Inamura S; Ito H; Shinagawa T; Tsutsumiuchi M; Taga M; Kobayashi M; Yokoyama O
Prostate; 2018 Jul; 78(10):743-752. PubMed ID: 29608020
[TBL] [Abstract][Full Text] [Related]
16. Urodynamic Features and Significant Predictors of Bladder Outlet Obstruction in Patients With Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia and Small Prostate Volume.
Kang M; Kim M; Choo MS; Paick JS; Oh SJ
Urology; 2016 Mar; 89():96-102. PubMed ID: 26683755
[TBL] [Abstract][Full Text] [Related]
17. Urodynamics and safety of the β₃-adrenoceptor agonist mirabegron in males with lower urinary tract symptoms and bladder outlet obstruction.
Nitti VW; Rosenberg S; Mitcheson DH; He W; Fakhoury A; Martin NE
J Urol; 2013 Oct; 190(4):1320-7. PubMed ID: 23727415
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic effects of silodosin, a new alpha 1A-adrenoceptor selective antagonist, for the treatment of benign prostatic hyperplasia.
Yamanishi T; Mizuno T; Tatsumiya K; Watanabe M; Kamai T; Yoshida K
Neurourol Urodyn; 2010 Apr; 29(4):558-62. PubMed ID: 19693954
[TBL] [Abstract][Full Text] [Related]
19. Do baseline estrogen and testosterone affect lower urinary tract symptoms (LUTS) prior to or after pharmacologic treatment with tadalafil?
Egan KB; Miner MM; Suh M; McVary K; Ni X; Roehrborn CG; Wittert G; Wong DG; Rosen RC
Andrology; 2015 Nov; 3(6):1165-72. PubMed ID: 26452447
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
